Unlock instant, AI-driven research and patent intelligence for your innovation.

Delta opioid receptor agonist compounds

a technology of opioid receptor and agonist, applied in the field of compositions and methods of treatment of sexual dysfunction, can solve the problems of low success rate, ineffectiveness for all patients, and inability to solve problems that never solve or reoccur, and achieve the effect of reducing sexual libido and reducing male sexual respons

Inactive Publication Date: 2007-07-26
ENTA HLDG
View PDF15 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The present invention relates to a method for delaying the onset of ejaculation during sexual stimulation by administering a pharmaceutical composition containing a delta opioid receptor agonist. The pharmaceutical formulation may also contain other active agents such as Viagra, Prozac, vasoactive agents, or a combination of two or more thereof. The method involves administering the pharmaceutical composition to a subject to delay the onset of ejaculation during sexual stimulation. The invention provides a safe and effective way to treat premature ejaculation."

Problems solved by technology

Although premature ejaculation is common, there is some disagreement on its precise cause and treatment.
However, since psychotherapy necessitates a long period of time for the doctor, patient and partner to work together in order to be effective, its success rate is low.
That is, changes in living style, external stress, etc., undermine its success such that the problem is never solved or it reoccurs.
However, these drugs may not be effective for all patients, and the side effects of these drugs can halt treatment or impair patient compliance.
Disease states or adverse interactions with other drugs may contraindicate the use of these compounds or require lower dosages that may not be effective to delay the onset of ejaculation.
Additionally, the stigma of mental illness associated with antidepressant therapy can discourage patients from beginning or continuing such treatments.
However, the administration of fluoxetine has many undesired aspects.
Patients with hepatic or renal impairments may not be able to use fluoxetine due to its metabolism in the liver and excretion via the kidney.
Systemic events during fluoxetine treatment involving the lungs, kidneys or liver have occurred, and death has occurred from overdoses.
In addition, side effects of oral fluoxetine administration include hair loss, nausea, vomiting, dyspepsia, diarrhea, anorexia, anxiety, nervousness, insomnia, drowsiness, fatigue, headache, tremors, dizziness, convulsions, sweating and skin rashes.
Paroxetine cannot be given to patients undergoing treatment with a monoamine oxidase inhibitor.
However, local anesthetics, such as lidocaine ointment or spray, may induce vasoconstriction, which may lead to transient erectile failure, and can be transferred to sexual partners thereby decreasing their sensitivity and pleasure as well.
Thus, present day drug therapy cannot successfully solve the problems associated with premature ejaculation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Delta opioid receptor agonist compounds
  • Delta opioid receptor agonist compounds
  • Delta opioid receptor agonist compounds

Examples

Experimental program
Comparison scheme
Effect test

example 1

4-((alpha-S)-alpha-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)benzyl)-N,N-diethylbenzamide

[0219] 4-Carboxybenzaldehyde (150 g, 100 mmol) was added to a 250 mL, 3-necked round bottom flask and stirred under nitrogen in 110 mL of toluene. Thionyl chloride (8.75 mL, 120 mmol) was added to the mixture, followed by the addition of 6 drops of DMF. A reflux condenser fitted with a calcium chloride drying tube was placed on the flask. The reaction was placed in an oil bath and heated at a bath temperature maintained below 120° C. The mixture was allowed to reflux for 1 hour after a clear solution was obtained and then cooled to room temperature. The solution was diluted with anhydrous toluene, and all volatiles were removed under vacuum.

[0220] The crude acid chloride was dissolved in 200 mL of dry tetrahydrofuran and cooled in an ice / water bath. Diethylamine (31.35 mL, 300 mmol) in 70 mL of dry tetrahydrofuran was added dropwise via an addition funnel. The cloudy solution was allowed to ...

example 2

4-((alpha-S)-alpha-((2S,5R)-2,5-Dimethyl-1-piperazinyl)benzyl)-N,N-diethylbenzamide

[0227] The compound of Example 1 was de-allylated by the method of Genet [J. P. Genet, S. Lemaire-Audoire, M. Savignac, Tetrahedron Letters, 36, 1267-1270 (1995)] as follows. A solution of 4-((alpha-S)-alpha-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)benzyl)-N,N-diethylbenzamide (Example 1, 8.392 g, 20 mmol) and thiosalicylic acid (3.70 g, 24 mmol) in anhydrous tetrahydrofuran (50 mL) was stirred under nitrogen for 3 h at room temperature with a catalyst solution prepared by dissolution of bis(dibenzylidineacetone)palladium (575 mg, 1.0 mmol) and 1,4-bis(diphenylphosphino)butane (426 mg, 1.0 mmol) in tetrahydrofuran (10 mL). The reaction mixture was evaporated to dryness, the residue dissolved in a mixture of ethyl acetate / ether (1:3, 300 mL) and extracted with 5% sodium carbonate solution (2×300 mL). The organic layer was diluted with two volumes of pentane and extracted with 3M-hydrochloric acid (...

example 3

4-((alpha-S)-alpha-((2S,5R)-2,5-Dimethyl-4-(3-fluorobenzyl)-1-piperazinyl)benzyl)-N,N-diethylbenzamide

[0228] A solution of 4-((alpha-S)-alpha-((2S,5R)-2,5-dimethyl-1-piperazinyl)benzyl)-N,N-diethylbenzamide (1.898 g, 5.0 mmol) in 25 mL acetonitrile was added to sodium iodide (75 mg, 0.5 mmol) and stirred during the addition of triethylamine (2.5 mL, 1.815 g, 17.94 mmol), followed by 3-fluorobenzyl bromide (1.227 mL, 1.89 g, 10.0 mmol). An immediate turbidity was observed on addition of the 3-fluorobenzyl bromide, thickening to a copious white precipitate over one hour. The flask was sealed under nitrogen and the suspension stirred overnight at room temperature. The reaction mixture was evaporated to dryness and the residue was partitioned between ethyl acetate (40 mL) and saturated sodium bicarbonate solution (10 mL). The supernatant organic layer was separated and the aqueous layer extracted further with ethyl acetate (2×40mL). The combined organic extracts were dried over anhydro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
widthaaaaaaaaaa
lengthaaaaaaaaaa
lengthaaaaaaaaaa
Login to View More

Abstract

Compositions and methods for treatment of sexual dysfunctions by administering to a subject a pharmaceutical composition comprising a delta opioid receptor agonist in an amount effective to delay the onset of ejaculation in the subject during sexual stimulation.

Description

CROSS-REFERENCE TO RELATED APPLICATION [0001] This application is a continuation of and claims priority from copending U.S. patent application Ser. No. 10 / 335,764, which in turn claims priority from U.S. Provisional Patent Application No. 60 / 345,216 filed on Jan. 2, 2002.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention relates to compositions and methods of treatment for sexual dysfunctions, and more particularly, to the treatment of premature ejaculation in male subjects by administration of delta receptor agonist compound(s), optionally in combination with other agents. [0004] 2. Description of the Related Art [0005] Premature ejaculation is one of the most common male sexual dysfunctions, estimated to affect up to 40% of men, irrespective of age. Premature ejaculation is defined as a persistent or recurrent ejaculation with minimal sexual stimulation before, on or shortly after penetration. Although premature ejaculation is common, there i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/495C07D241/04A61K31/00A61K31/445A61K31/519A61K38/33
CPCA61K31/00A61K31/445A61K31/495A61K31/519A61K38/33C07D241/04A61K2300/00A61P15/00A61P15/10
Inventor CHANG, KWEN-JENKING, KLIMBICIUNAS, KESTUTIS P.MCNUTT, ROBERT W. JR.PENDERGAST, WILLIAMJAN, SHYI-TAI
Owner ENTA HLDG